Clinical

Dataset Information

0

Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab


ABSTRACT: -1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients. The present study aims to prospectively evaluate the predictive role of this polymorphism in metastatic colorectal patients receiving the same treatment.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2107435 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2020-08-01 | E-MTAB-8734 | biostudies-arrayexpress
2009-07-25 | E-GEOD-17314 | biostudies-arrayexpress
| PRJEB13480 | ENA
2010-05-27 | E-GEOD-6646 | biostudies-arrayexpress
| S-EPMC8976085 | biostudies-literature
2008-01-03 | GSE6646 | GEO
| PRJEB20412 | ENA
| S-EPMC4741865 | biostudies-literature
| PRJEB61146 | ENA
| PRJEB48922 | ENA